New-generation Antipsychotics and Cardiovascular Risk
- 9 Downloads
Purpose of Review
To critically review the current landscape of literature on cardiotoxicity of “new-generation antipsychotics,” defined as those approved by the Food and Drug Administration in the last 10 years.
There is a paucity of data regarding the cardiovascular risks of these medications. Based on the investigations that have been published, iloperidone appears to be the greatest risk of corrected QT prolongation followed by asenapine whereas lurasidone, cariprazine, and brexpiprazole were not found to have significant effects on corrected QT. However, the evidence was low quality. In terms of metabolic effects, asenapine, iloperidone, cariprazine, and brexpiprazole all had mild to moderate effects whereas lurasidone had no significant effects observed.
Further investigation is warranted for all of these medications to better understand their cardiovascular effects.
KeywordsAntipsychotics Cardiotoxicity Brexpiprazole Cariprazine Asenapine Iloperidone
We would like to acknowledge Elaine Alligood for her assistance in literature search and article access.
Compliance with Ethical Standards
Conflict of Interest
Aishwarya K. Rajagopalan, William K. Bache, Serena Z. Chen, Ermal Bojdani, and Kevin J. Li declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 3.•Zhang Y, Liu Y, Su Y, You Y, Ma Y, Yang G, et al. The metabolic side effects of 12 antipsychotic drugs used for the treatment of schizophrenia on glucose: a network meta-analysis. BMC Psychiatry. 2017;17(1):373. https://doi.org/10.1186/s12888-017-1539-0.Important non-industry sponsored network meta-anaylsis that compares the metabolic effects of 12 different antipsychotic medications.
- 4.Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Kissling W, et al. Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophr Bull. 2012;38(1):167–77. https://doi.org/10.1093/schbul/sbq042.Google Scholar
- 5.•Stoner SC. Management of serious cardiac adverse effects of antipsychotic medications. Ment Health Clin. 2017;7(6):246–54. https://doi.org/10.9740/mhc.2017.11.246.Brief but thorough education focused article centered on treatment of antipsychotic related cardiovacsular toxicity.
- 8.•Durgam S, Landbloom RP, Mackle M, Wu X, Mathews M, Nasrallah HA. Exploring the long-term safety of asenapine in adults with schizophrenia in a double-blind, fixed-dose, extension study. Neuropsychiatr Dis Treat. 2017;13:2021–35. https://doi.org/10.2147/NDT.S130211.Although industry sponsored, this study with 120 patients across multiple sites compares tolerability of low-dose asenapine, high-dose asenapine, and olanzapine.
- 12.Potkin SG, Cohen M, Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. J Clin Psychiatry. 2007;68(10):1492–500.Google Scholar
- 13.Gill JS, Sulaiman AH. QTc prolongation and ventricular trigemini with asenapine: a case report. Turk Psikiyatri Derg. 2018;29(1):67–8.Google Scholar
- 20.Mathis MV. FDA Summar Review: Iloperidone. In: (FDA) FaDA, editor.2009. p. 1–21. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022192s017lbl.pdf.
- 28.Citrome L, Weiden PJ, Alva G, Glick ID, Jackson R, Mattingly G, et al. Switching to iloperidone: an omnibus of clinically relevant observations from a 12-week, open-label, randomized clinical trial in 500 persons with schizophrenia. Clin Schizophr Relat Psychoses. 2015;8(4):183–95. https://doi.org/10.3371/CSRP.CIWE.103114.Google Scholar
- 30.Mathis MV. FDA Summary review: lurasidone. In: (FDA) FaDA, editor. 2010. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/200603lbls10s11.pdf.
- 34.Mathis MV. FDA summary review: cariprazine. 2015. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/204370lbl.pdf.
- 35.Girgis RR, Slifstein M, D’Souza D, Lee Y, Periclou A, Ghahramani P, et al. Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNO. Psychopharmacology. 2016;233(19–20):3503–12. https://doi.org/10.1007/s00213-016-4382-y.Google Scholar
- 36.Kiss B, Horvath A, Nemethy Z, Schmidt E, Laszlovszky I, Bugovics G, et al. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther. 2010;333(1):328–40. https://doi.org/10.1124/jpet.109.160432.Google Scholar
- 37.Lao KS, He Y, Wong IC, Besag FM, Chan EW. Tolerability and safety profile of cariprazine in treating psychotic disorders, bipolar disorder and major depressive disorder: a systematic review with meta-analysis of randomized controlled trials. CNS Drugs. 2016;30(11):1043–54. https://doi.org/10.1007/s40263-016-0382-z.Google Scholar
- 38.Durgam S, Greenberg WM, Li D, Lu K, Laszlovszky I, Nemeth G, et al. Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study. Psychopharmacology. 2017;234(2):199–209. https://doi.org/10.1007/s00213-016-4450-3.Google Scholar
- 42.Mathis MV. FDA summary review: brexpiprazole. 2015. p. 1–17.Google Scholar
- 46.Citrome L. Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2015;69(9):978–97. https://doi.org/10.1111/ijcp.12714.Google Scholar